Fig. 2From: Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic reviewPRISMA diagram of study selection with reported CSF levels for nivolumab or ipilimumabBack to article page